TargetBeta
P4HTM
prolyl 4-hydroxylase, transmembrane · also P4H-TM, PHD4, PH4, HIFPH4 · Iron (II) and 2-oxoglutarate dependent oxygenases
2 programs in company-led studies act on P4HTM, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| roxadustatrule | Astellas Pharma | phase 4 | 472 running | EGLN1, EGLN2, EGLN3 | ChEMBL |
| daprodustatrule | GlaxoSmithKline | phase 3 | 331 running | EGLN1, EGLN2, EGLN3 | ChEMBL |
Conditions their studies are in
- Anemia, 2 programs
- Diabetic Foot, 1 program
- Kidney Failure, Chronic, 1 program
- Myelodysplastic Syndromes, 1 program
- Peripheral Vascular Diseases, 1 program
- Renal Insufficiency, 1 program
- Renal Insufficiency, Chronic, 1 program
- Tendon Injuries, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- May 2027daprodustat · GlaxoSmithKline · phase 3 · NCT07300111
- Oct 30, 2027roxadustat · Astellas Pharma · phase 4 · NCT05970172
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.